http://www.fool.com/News/mft/2006/mft06110718.htm?ref=foolwatchAbraxis AdvancesBy Brian Lawler November 7, 2006 Nothing gets pharmaceutical investors more lathered-up than a drug developer with a so-called platform technology -- one that can be used to make existing drugs more potent, longer lasting, or safer, for example. Platform technologies are so exciting because they can potentially be applied across many already approved drugs, capturing a good chunk of an existing drug's market share. This is why investors have been so excited about Abraxis BioScience (Nasdaq: ABBI) since the approval of its cancer-treating compound, Abraxane, back in early 2005......
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rati